Medpace Holdings, Inc. $MEDP Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 149,948 shares of the company’s stock after purchasing an additional 11,838 shares during the period. Natixis Advisors LLC owned 0.53% of Medpace worth $77,097,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of MEDP. Clarkston Capital Partners LLC acquired a new stake in Medpace during the second quarter worth about $40,569,000. Cibc World Market Inc. bought a new stake in shares of Medpace in the 3rd quarter worth approximately $5,033,000. Brighton Jones LLC lifted its holdings in shares of Medpace by 160.4% in the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after purchasing an additional 2,501 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Medpace by 150.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after purchasing an additional 9,117 shares during the period. Finally, Baillie Gifford & Co. boosted its position in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Up 0.3%

Shares of NASDAQ MEDP opened at $470.59 on Monday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92. The company has a market cap of $13.36 billion, a price-to-earnings ratio of 30.76, a P/E/G ratio of 2.26 and a beta of 1.44. The business has a fifty day simple moving average of $533.94 and a 200-day simple moving average of $539.47.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s revenue was up 32.0% on a year-over-year basis. During the same quarter last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of several analyst reports. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Mizuho set a $582.00 price objective on shares of Medpace in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada started coverage on shares of Medpace in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.